Journal
ACTA CYTOLOGICA
Volume 63, Issue 2, Pages 159-168Publisher
KARGER
DOI: 10.1159/000497617
Keywords
Papillomavirus infections; HPV vaccines; Clinical efficacy; Clinical trials; State of the art reviews
Categories
Ask authors/readers for more resources
HPV is the most common sexually transmitted biological agent and is the cause of many conditions in men and women, including precancer lesions and cancer. Three prophylactic HPV vaccines targeting high-risk HPV types are available in many countries worldwide: 2-, 4- and 9-valent vaccines. All the 3 vaccines use recombinant DNA technology and are prepared from the purified L1 protein that self-assembles to form HPV type-specific empty shells. This non-systematic review aims to summarize the HPV epidemiology and the vaccine development to review the landmark trials of HPV vaccine, to present to most remarkable results from clinical trials and the real world, and to stress the challenges and the barriers for HPV vaccine implementation. (C) 2019 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available